Patents by Inventor Joseph Walters
Joseph Walters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132477Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.Type: ApplicationFiled: December 13, 2021Publication date: April 25, 2024Applicant: Pfizer Inc.Inventors: Scott William Bagley, Agustin Casimiro Garcia, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
-
Publication number: 20240124439Abstract: The invention relates to imidazopyridines of Formula (I) and pharmaceutically acceptable salts thereof, wherein R0 to R5 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.Type: ApplicationFiled: December 13, 2021Publication date: April 18, 2024Applicant: Pfizer Inc.Inventors: Scott William Bagley, Agustin Casimiro-Garcia, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Katherine Lin Lee, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
-
Publication number: 20240124450Abstract: A compound of formula I having the structure: or a pharmaceutically acceptable salt thereof, wherein A1 and A2 are independently O or S; X is selected from CH2, CD2, NR3, O, and S, where R3 is selected from hydrogen, C1-C4 linear or branched chain alkyl, halo(C1-C4)linear or branched chain alkyl, and hydroxyl(C1-C4)linear or branched chain alkyl; Y and Z are selected from C and N, where when Y is C, then Z is N, and when Y is N, then Z is C; R1 and R2 are independently selected from hydrogen, deuterium, C1-C4 linear or branched chain alkyl, etc.; or a C1-C2 alkyl substituted with a C3-C5 cycloalkyl ring; or taken together to form a C3-C6 cycloalkyl ring; or where X is CH2 or CD2, then R1 and R2 are independently selected from hydrogen, deuterium, halogen, hydroxyl, C1-C4 linear or branched chain alkyl, etc.; R4 is selected from hydrogen, deuterium, cyano, halogen, (C1-C3) alkoxy, etc.; R5 is selected from hydrogen, deuterium, halogen, C1-C3 alkoxy, amino, (C1-C4 linear or branched chain alkyl)amino, etc.Type: ApplicationFiled: September 13, 2023Publication date: April 18, 2024Applicant: Pfizer Inc.Inventors: Andrea Nicole Bootsma, David Christopher Ebner, Daniel Wei-Shung Kung, Matthew Alexander Perry, Daniel Copley Schmitt, Joseph Walter Strohbach, Atli Thorarensen
-
Patent number: 11929670Abstract: Systems, methods, and devices for converting electric power are disclosed. Converter modules convert power in a configurable manner in conjunction with a controller.Type: GrantFiled: August 3, 2023Date of Patent: March 12, 2024Assignee: CisLunar Industries USA, Inc.Inventors: Steven R Ward, Jan Walter Schroeder, Joseph W Pawelski, Toby Joseph Daniel Mould
-
Publication number: 20240069578Abstract: A control system is configured to monitor operation of a flow control, like a control valve. These configurations can use of continuous or real-time data to evaluate fitness or function of the device under operating conditions. This feature can alert operators to problems or issues with one or more devices, or process lines in total. These problems may, for example, indicate that a valve is incorrectly sized for actual working conditions. As a result, engineers may find that the valve is too big (or oversize) or too small (or undersize) because the design process for layout of the process line relies upon a design load that reflects a future maximum (plus some factor of safety), and not the actual working conditions that might prevail once the device is in service in the field.Type: ApplicationFiled: August 31, 2022Publication date: February 29, 2024Inventors: Vladimir Dimitrov Kostadinov, Joseph Georges Shahda, Cyril Nicolas Vlassoff, Jeremy Asher Glaun, David Chunhe Zhou, Christopher Bittner, Justin Walter Betley
-
Publication number: 20240010152Abstract: A vehicle includes one or more sensors and engages at least one of the one or more sensors to evaluate at least one of a count or location of vehicle occupants prior to an incident. The vehicle determines that an incident has occurred and that at least one of an evaluated count or location of at least one vehicle occupant has changed following the incident. Also, the vehicle engages at least one of the one or more sensors to detect a presence of a prior occupant outside the vehicle following the incident, responsive to determining that the at least one of the evaluated count or location of the at least one vehicle occupant changed and, responsive to detecting the presence of the prior occupant outside the vehicle following the incident, reports the presence to a 3rd party response entity.Type: ApplicationFiled: July 8, 2022Publication date: January 11, 2024Inventors: Joseph Walter Neal, Jeremy Lerner, Mohammad Abouali, Ali Abdallah, Xingping Chen, Scott Huggins
-
Publication number: 20230339960Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.Type: ApplicationFiled: June 28, 2023Publication date: October 26, 2023Inventors: JOHN DAVID TRZUPEK, KATHERINE LIN LEE, MARK EDWARD BUNNAGE, SEUNGIL HAN, DAVID HEPWORTH, FRANK ELDRIDGE LOVERING, JOHN PAUL MATHIAS, NIKOLAOS PAPAIOANNOU, BETSY SUSAN PIERCE, JOSEPH WALTER STROHBACH, STEPHEN WAYNE WRIGHT, CHRISTOPH WOLFGANG ZAPF, LORI KRIM GAVRIN, ARTHUR LEE, DAVID RANDOLPH ANDERSON, KEVIN JOSEPH CURRAN, CHRISTOPH MARTIN DEHNHARDT, EDDINE SAIAH, JOEL ADAM GOLDBERG, XIAOLUN WANG, HORNG-CHIH HUANG, RICHARD VARGAS, MICHAEL DENNIS LOWE, AKSHAY PATNY
-
Publication number: 20230280220Abstract: The invention relates to benzimidazoles of Formula (1) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (1) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.Type: ApplicationFiled: April 17, 2023Publication date: September 7, 2023Applicant: Pfizer Inc.Inventors: Scott William Bagley, Agustin Casimiro Garcia, Xiayun Cheng, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
-
Publication number: 20230250100Abstract: The present invention relates to methods of using compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.Type: ApplicationFiled: April 13, 2023Publication date: August 10, 2023Inventors: Joseph Walter Strohbach, David Christopher Limburg, John Paul Mathias, Atli Thorarensen, Rajiah Aldrin Denny, Christoph Wolfgang Zapf, Daniel Elbaum, Lori Krim Gavrin, Ivan Viktorovich Efremov
-
Patent number: 11702424Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: GrantFiled: August 18, 2020Date of Patent: July 18, 2023Assignee: Pfizer Inc.Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
-
Publication number: 20230219963Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.Type: ApplicationFiled: May 25, 2021Publication date: July 13, 2023Applicant: Pfizer Inc.Inventors: Martin Eugene Dowty, Bimal Kumar Malhotra, Ivan Jordan Samardjiev, Brian Matthew Samas, Joseph Walter Strohbach
-
Patent number: 11661419Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.Type: GrantFiled: December 18, 2020Date of Patent: May 30, 2023Assignee: Pfizer Inc.Inventors: Scott William Bagley, Agustin Casimiro-Garcia, Xiayun Cheng, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
-
Publication number: 20230148402Abstract: The present invention relates to boron containing compounds of Formula (I) X—Y—Z ??Formula (I) that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.Type: ApplicationFiled: December 15, 2022Publication date: May 11, 2023Applicant: Pfizer Inc.Inventors: Tsutomu Akama, David Clive Blakemore, Robert Toms Jacobs, Peter Jones, David Christopher Limburg, Martins Sunday Oderinde, Matthew Alexander Perry, Jacob John Plattner, Joseph Walter Strohbach, Rubben Federico Torella, Thean Yeow Yeoh, Yasheen Zhou
-
Patent number: 11559538Abstract: The present invention relates to boron containing compounds of Formula (IA): that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.Type: GrantFiled: October 28, 2020Date of Patent: January 24, 2023Assignee: Pfizer Inc.Inventors: Joseph Walter Strohbach, Tsutomu Akama, David Clive Blakemore, Robert Toms Jacobs, Peter Jones, David Christopher Limburg, Martins Sunday Oderinde, Matthew Alexander Perry, Jacob John Plattner, Rubben Federico Torella, Yasheen Zhou, Thean Yeow Yeoh
-
Patent number: 11390623Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.Type: GrantFiled: January 23, 2020Date of Patent: July 19, 2022Assignee: PFIZER INC.Inventors: Thomas Allen Chappie, Jaclyn Louise Henderson, Joseph Michael Young, Travis T. Wager, Bethany Lyn Kormos, Nandini Chaturbhai Patel, Simone Sciabola, Jamison Bryce Tuttle, Patrick Robert Verhoest, Joseph Walter Tucker
-
Publication number: 20220153874Abstract: Provided are novel dipeptide repeat (DPR) specific antibodies (e.g., human-derived antibodies) as well as synthetic variants and biotechnological derivatives thereof, capable of binding C9orf72 poly-glycine-alanine DPRs, as well as methods and uses related thereto. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.Type: ApplicationFiled: April 25, 2019Publication date: May 19, 2022Inventors: Jan Grimm, Fabio Montrasio, Isin Dalkilic-Liddle, Mia Marie Rushe, Joseph Walter Arndt
-
Patent number: 11275981Abstract: An object with an icon thereon encodes a bit sequence. The icon comprises a plurality of concentric rings, each of the plurality of concentric rings is divided into a plurality of data sectors. Each of the plurality of data sectors is associated with a corresponding bit in the bit sequence, and each of the plurality of data sectors encodes the corresponding bit based on the presence or absence of a line segment in the sector. The plurality of concentric rings further comprises at least three anchor sectors on one or more of the plurality of concentric rings, the at least three anchor sectors comprise an anchor mark. The plurality of concentric rings further comprises one or more error correction sectors, each of the one or more error correction sectors encodes a corresponding error correction bit based on the presence or absence of a line segment in the error correction sector.Type: GrantFiled: April 30, 2018Date of Patent: March 15, 2022Assignee: THE COCA-COLA COMPANYInventors: William Patrick Brandt, Joseph Walter Bechely, IV, Lucas Persona, Daniel Nicoletti
-
Publication number: 20220062404Abstract: Crimean-Congo hemorrhagic fever virus (CCHFV) is an important human pathogen. Limited evidence suggests that antibodies can protect humans against lethal CCHFV disease, but the protective efficacy of antibodies has never been evaluated in adult animal models. Here adult mice were used to investigate the protection provided by glycoprotein-targeting neutralizing and non-neutralizing monoclonal antibodies (mAbs) against CCHFV infection. A single non-neutralizing antibody (mAb-13G8) was identified that protected adult type I interferon deficient mice >90% when treatment was initiated prior to virus exposure and >60% when administered after virus exposure. Neutralizing antibodies known to protect neonatal mice from lethal CCHFV infection, failed to confer protection regardless of IgG subclass. The target of mAb-13G8 was identified as GP38, one of multiple proteolytically-cleaved glycoproteins derived from the CCHFV glycoprotein precursor polyprotein.Type: ApplicationFiled: January 7, 2020Publication date: March 3, 2022Inventors: Aura Rae GARRISON, Charles Jason SHOEMAKER, Joseph Walter GOLDEN
-
Patent number: 11219522Abstract: A buoy system for treating cardiac valve regurgitation comprising a movable plug having atrial and ventricular ends, wherein a through-hole passes from the atrial to the ventricular end, wherein during systole, the plug travels toward a cardiac atrium, wherein during diastole, the plug travels into a cardiac ventricle; a tether having atrial and ventricular ends, wherein the tether passes through the through-hole of the moving plug, wherein the atrial end of the tether projects into an atrium, wherein the atrial end of the tether includes a cap to engage a delivery tool; at least one distal anchor located in the ventricle, wherein the distal anchor is coupled to the ventricular end of the tether, and wherein the system is percutaneously delivered and optionally recaptured via catheter and recapture tool at the cap of the tether, respectively.Type: GrantFiled: May 25, 2018Date of Patent: January 11, 2022Assignees: THE JOHNS HOPKINS UNIVERSITY, BOSTON SCIENTIFIC SCIMED, INC.Inventors: Ramji Rengarajan, Victor San Hou Yu, Kalyna Sconzert, Tom Jancaric, Reggie Roth, James Cawthra, Dennis Werner, Jason Kilvington, Umang Anand, George L. Coles, James Duncan Beaty, Keith Bulkin, Joseph A. Walters, Timothy P. Harrigan, Kenton J. Zehr, Todd Christopher Crawford
-
Patent number: D959962Type: GrantFiled: August 11, 2020Date of Patent: August 9, 2022Inventor: Joseph Walter Acton